Dark Horse Consulting and Beijing-based KunTuo Research and Development announced a memorandum of understanding to streamline cell and gene therapy trial execution in China. The agreement is designed to combine KunTuo’s advanced-therapy trial experience with Dark Horse’s regulatory strategy capabilities, while also aiming to preserve data reuse for submissions outside China. KunTuo positions itself as a trial services provider founded by IQVIA, citing support for more than 1,000 drug trials with a majority involving advanced therapies. Dark Horse said the partnership expands its integrated offerings for sponsors working through Chinese regulatory pathways, including an emphasis on producing globally usable clinical trial datasets. For global developers of CGT, the MOU signals continued efforts to reduce friction around multi-region development and regulatory alignment—especially as sponsors look to accelerate enrollment and later broaden into other markets using the same evidence package.